Hormone therapy for postmenopausal osteoporosis management

Abstract

Menopausal hormone therapy (MHT) has been used for prevention and treatment of postmenopausal osteoporosis for several decades. However, public concerns were raised over the safety of MHT after the initial report was published in 2002 by the Women’s Health Initiative. We conducted a historical review on this subject, primarily focusing on level I evidence from randomized controlled trials, systematic reviews and meta-analyses, and summarized high-quality evidence on the efficacy and safety of MHT in management of postmenopausal osteoporosis. Clinical issues were also discussed on MHT initiation, identification of treatment candidates and treatment duration, as well as discontinuation of MHT.

绝经后骨质疏松症的激素治疗 摘要

几十年来, 绝经激素治疗(MHT)一直用于预防和治疗绝经后骨质疏松症。然而, 在妇女健康倡议于2002年初次发表后, 公众对MHT的安全性表示担忧。我们对这一主题进行了历史回顾, 主要集中于随机对照试验、系统评价和meta分析的一级证据, 并总结了MHT治疗绝经后骨质疏松症有效性和安全性的高质量证据。也讨论了MHT启动、治疗适应证、治疗持续时间以及MHT的终止。

Keywords:

• Hormone therapy
• postmenopausal osteoporosis
• osteoporosis

Potential conflict of interest

X. Jiang has no conflict of interest. R. Kagan has served as a consultant to Amgen, Astellas, Pharmavite and Therapeutics MD.

Source of funding

This work and manuscript preparation were unfunded.